MedTrace Logo

Intranasal Oxytocin in the Treatment of Autism

NCT00490802 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2015-10-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn whether or not the drug called oxytocin is helpful in improving mood and social functioning in adults with autism.

Conditions

Interventions

DRUG

Oxytocin

Intranasal Oxytocin

DRUG

Placebo

Placebo Comparator

Sponsors & Collaborators

Principal Investigators

  • Evdokia Anagnostou, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2011-09-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00490802 on ClinicalTrials.gov